Mitotic MTH1 Inhibitors in Treatment of Cancer

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• The DNA damage response (DDR) protein MTH1 sanitizes the oxidized dNTP pool, preventing oxidative DNA damage.
• MTH1 is a stress-induced protein overexpressed in cancer, with an emerging role in mitosis.

Purpose of the Study:

• To discuss the leading mitotic MTH1 inhibitor TH1579 (OXC-101, karonudib) and its dual effects on mitosis and DNA damage in cancer cells.
• To explore why MTH1 inhibitors that solely inhibit enzyme activity may fail to kill cancer cells.
• To evaluate MTH1 as a valid cancer treatment target and discuss its emerging roles in tubulin polymerization and mitosis.

Main Methods:

• Review of existing literature on MTH1 function and inhibitors.
• Discussion of TH1579's mechanism of action and clinical trial status.
• Analysis of MTH1's role in mitosis and tubulin polymerization.

Main Results:

• Mitotic MTH1 inhibitors arrest cells in mitosis, leading to oxidative DNA damage and selective cancer cell killing.
• TH1579 exhibits dual effects on mitosis and oxidative DNA damage incorporation in cancer cells.
• The efficacy of MTH1 inhibitors solely targeting enzyme activity requires further investigation.

Conclusions:

• MTH1 inhibitors, particularly TH1579, demonstrate potential in cancer therapy by inducing DNA damage and disrupting mitosis.
• Further research is needed to understand MTH1's role in tubulin polymerization and mitosis for effective translational efforts.
• Edgetic perturbation presents challenges in validating DDR targets for cancer treatment.